RE:RE:RE:RE:RE:RE:My dream isMore than anything, I think this shows that Akero is now looked
at as a serious NASH player -they've made it to that status so NASH
analysts pick it up to be "thorough" in their coverage.
Probably also hit various market cap & trading hurdles.
I am hopeful that if we see POC on TH1902 and they get
Breakthrough & Accellerated and a financial model can be built
around their indications and commercial program (plus any
partnerships they add) that supports a robust investment
thesis, that they too will be looked at as a serious oncology
player that needs to be covered by biotech and oncology
analysts.
For a starter, I would think anyone who covers (covered) IMMU,
SeaGen or Bicycle should cover THTX. Those kind of pickups
with no banking carrot being held out indicate you've made it to
the bigtime with the analysts.